middle.news
Anteris Advances DurAVR Trial with FDA Submission, Hits 100 Patients Treated
2:36am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Anteris Advances DurAVR Trial with FDA Submission, Hits 100 Patients Treated
2:36am on Monday 2nd of June, 2025 AEST
Key Points
FDA IDE application submitted for DurAVR pivotal PARADIGM Trial
100 patients successfully treated with DurAVR Transcatheter Heart Valve
One-year clinical data shows sustained favorable outcomes and safety
Manufacturing capacity tripled to support upcoming trial and demand
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE